Navigation Links
Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Date:11/4/2007

bert A. Harrington, M.D., Professor of Medicine, Duke University Medical Center, and Director, Duke Clinical Research Institute. "I'm looking forward to seeing data from phase II and phase III studies with the REG1 drug:antidote system."

"The data from the Phase 1c study addressed important questions, particularly regarding the ability to titrate the RB007 component and therefore 'dial down' the anticoagulant effect of RB006," stated Doug Gooding, Chief Executive Officer of Regado Biosciences. "Based upon our Phase I study results, we developed an extensive Phase II program to evaluate REG1 in a variety of coronary revascularization settings. The first study is actively enrolling patients and we expect to initiate several additional studies over the coming months."

REVERSAL-PCI, a multi-center, open-label, randomized Phase IIa clinical study of the REG1 anticoagulation system, will enroll 26 patients undergoing elective percutaneous coronary intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon angioplasty dilatation and stenting in patients at low risk for complications associated with therapy-related bleeding or heart attack.

About REG1 Anticoagulation System

Regado's lead product candidate, REG1, is the first specific, direct- acting, antidote-controlled anticoagulant ever described. Regado is developing REG1 for use in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures. These procedures, which include coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), put patients at a high-risk for therapy-related bleeding complications. REG1 is being developed initially to increase therapeutic flexibility and improve patient outcomes in coronary revascularization procedures.

REG1 is a two-component system, consisting of an aptamer-based anticoagulant and its matched antidote. The REG1 anticoagulant co
'/>"/>

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Influenza will affect as many as 200,000 people this ... States as high as 49,000 people.  The main ... person to person in respiratory droplets of coughs and sneezes. ... but kills much fewer people each year than the Flu. ... including sweat, saliva, blood and other bodily fluids. The Ebola ...
(Date:10/22/2014)... 2014 InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) ... revolutionizing spinal cord injury (SCI) treatment with their novel ... in tissue regrowth in the spinal cord area when ... FDA approved polymer, the scaffold ultimately breaks down to ... human body. NVIV has recently attracted significant investor attention ...
(Date:10/22/2014)... 22, 2014 WHEN: Wednesday, October 29, 2014 ... available at: http://bit.ly/1yStiU9 SPEAKERS: Visionary ... Visionary Innovation Research Group Senior Research Analyst ... materials, nanobots and flexible electronics are among ... our lives in the coming decades. These ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4
(Date:10/22/2014)... (HealthDay News) -- Measures taken by Firestone officials at ... may have limited the spread of the disease there ... Firestone Natural Rubber Co. provides health services to about ... densely populated communities. Between Aug. 1 and Sept. ... among those 80,000 people. That incidence rate of 0.09 ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... MA (PRWEB) October 20, 2014 ... sponsoring a booth at the American Foundation for Suicide ... 25th. The AFSP is a not-for-profit organization that hosts ... Net proceeds from these events are used to help ... but education and personal relationships as well. , ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 T.E.N., ... relationship-marketing firm, announced today that William H. Murray, ... the 2014 ISE® Luminary Leadership Award winner. Presented ... achievements of an outstanding leader and industry practitioner ... contributions in advancing the information security industry. , ...
(Date:10/20/2014)... Angeles, CA (PRWEB) October 20, 2014 ... fitness expertise, nutritional coaching, corporate wellness programming, authorship, international ... CPT, is excited to announce the release of the ... , After many years of coaching thousands of individuals ... nutrition tracking app that does not require calorie counting ...
Breaking Medicine News(10 mins):Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3
... , , , ... week pooled results from two Phase 3 studies (DUET-1 ... with non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor ... RNA copies/mL) while taking INTELENCE(TM) (etravirine) tablets plus background ...
... found those kids performed worse on intelligence tests at ... Fetal exposure to high levels of a common airborne ... children, a new study suggests. , The finding is ... living in the New York City area. Specifically, it ...
... , TAMPA, Fla. July 20 Health ... appointment of Michael Unhjem as a member of its board of directors. ... http://www.newscom.com/cgi-bin/prnh/20090709/FL43703LOGO ) , , ... Shield (BCBS) of North Dakota, was unanimously elected to Health Integrated,s board ...
... , , , ... company focused on global eClinical solutions for the clinical trials industry, ... member of the DATATRAK CRO Connect Program(TM). ARA will utilize ... efficiently serve its paper and EDC clients. , ...
... , , CHICAGO, ... ) announced today that Diane Adams has joined the Company as ... more than 20 years of finance, field operations and human resources ... of Human Resources for Worldwide Sales and International Theaters at Cisco, ...
... 20 News briefs concerning economic and business growth in the Tampa ... , USF Poly Unveils Plans for ... announced plans to open two business incubators this fall. The facilities ... name Blue Sky, will be the first public business technology incubators in ...
Cached Medicine News:Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 2Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 3Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 4Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 5Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 6Health News:Exposure to Common Pollutant in Womb Might Lower IQ 2Health News:Exposure to Common Pollutant in Womb Might Lower IQ 3Health News:Michael Unhjem Appointed to Board of Directors for Health Integrated 2Health News:Michael Unhjem Appointed to Board of Directors for Health Integrated 3Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 2Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 3Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 4Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 2Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 3Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 4Health News:Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs) 2Health News:Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs) 3Health News:Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs) 4